Introduction {#cam41521-sec-0001}
============

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, and its morbidity and mortality increase each year [1](#cam41521-bib-0001){ref-type="ref"}. In recent years, many advances in medical technology have been made, but liver cancer treatment commonly comprises surgical resection combined with radiofrequency ablation, interventional embolization, and targeted molecular therapies [2](#cam41521-bib-0002){ref-type="ref"}, [3](#cam41521-bib-0003){ref-type="ref"}, [4](#cam41521-bib-0004){ref-type="ref"}. However, most patients miss their opportunity to receive radical treatment because they have already reached an advanced stage of liver cancer by their first visit [5](#cam41521-bib-0005){ref-type="ref"}, [6](#cam41521-bib-0006){ref-type="ref"}. Therefore, it is of great importance to further explore the pathogenesis of HCC and to determine highly selective therapeutic targets for HCC prognosis to facilitate clinical HCC studies and improve the efficacy of HCC treatment.

Like many other solid cancers, the role of the tumor cell microenvironment is considered to be key in HCC development [7](#cam41521-bib-0007){ref-type="ref"}. With the exception of the traditional oxidative oxidation of glucose to pyruvate via the mitochondrial tricarboxylic acid cycle, the energy required for cancer cells comes from the anaerobic glycolysis of glucose [8](#cam41521-bib-0008){ref-type="ref"}. In this process, glucose is converted to lactate by lactate dehydrogenase in cancer cells (Warburg effect) [9](#cam41521-bib-0009){ref-type="ref"}. The formation and regeneration of hepatocellular lesions, as well as neovascularization, are also closely linked to hepatocyte anaerobic glycolysis [10](#cam41521-bib-0010){ref-type="ref"}. Lactate efflux occurs through the lactate‐activated transcription factor hypoxia‐induced factor 1α (HIF1α), which induces glucose transporter 1 (GLUT1), LDH‐A, and monocarboxylate transporters [11](#cam41521-bib-0011){ref-type="ref"}, [12](#cam41521-bib-0012){ref-type="ref"}, particularly monocarboxylic acid transporter 4 (MCT4) [13](#cam41521-bib-0013){ref-type="ref"}. The maintenance of glycolysis requires continuous lactic acid excretion from the cells by a group of monocarboxylic acid transporters; in this process, MCT4 promotes the transport of short‐chain carbohydrates, such as pyruvate and lactate, to maintain intracellular pH levels and glycolysis [14](#cam41521-bib-0014){ref-type="ref"}. MCT4 is highly expressed in lung cancer, renal cell carcinoma [15](#cam41521-bib-0015){ref-type="ref"}, breast cancer [16](#cam41521-bib-0016){ref-type="ref"}, and pancreatic cancer [17](#cam41521-bib-0017){ref-type="ref"}, and high levels of MCT4 expression are associated with a high apoptotic index [18](#cam41521-bib-0018){ref-type="ref"}.

In this study, we evaluated the metabolic status of HCC tissues by assessing MCT4 and GLUT1 expression. We also analyzed the prognostic significance of the expression of these transporters in patients with HCC.

Materials and Methods {#cam41521-sec-0002}
=====================

Patients and samples {#cam41521-sec-0003}
--------------------

This study was performed strictly in accordance with the Helsinki Declaration. The Sun Yat‐sen University Cancer Center Research Ethics Committee approved this study, and all patients provided informed consent. Tumor and matched adjacent nontumorous tissues were consecutively collected from 213 patients with HCC during curative resection from December 2002 to November 2010 at Sun Yat‐sen University Cancer Center (Guangzhou, China). Diagnostic criteria were used to assess the postoperative pathology and were based on the criteria of the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC). All patients had complete medical history data. The criteria for inclusion in the study were as follows: (1) no anticancer treatment or distant metastasis prior to surgery; (2) no concurrent autoimmune diseases, HIV, or syphilis; and (3) follow‐up data were available. Patients classified as Child--Pugh class B or C were excluded from our study, as well as patients who had radical liver cancer surgery. Detailed clinicopathological parameters are listed in Table [1](#cam41521-tbl-0001){ref-type="table"}.

###### 

Clinical characteristics of patients with hepatocellular carcinoma

  Clinicopathological variable   Median (range)        No. of patients   \%
  ------------------------------ --------------------- ----------------- ------
  Age (year)                     50 (16--77)                             
  Gender                                                                 
  Female                                               31                14.6
  Male                                                 182               85.4
  HBsAg                                                                  
  Negative                                             31                14.6
  Positive                                             182               85.4
  Serum AFP (ng/mL)              172.7 (0--121000.0)                     
  Tumor size (cm)                6.4 (1.6--15.6)                         
  Tumor number                                                           
  Solitary                                             148               69.5
  Multiple                                             65                30.5
  Microvascular invasion                                                 
  No                                                   172               80.8
  Yes                                                  41                19.2
  Differentiation grade                                                  
  I                                                    15                7.0
  II                                                   104               48.8
  III                                                  90                42.3
  IV                                                   4                 1.9
  BCLC stage                                                             
  0                                                    4                 1.9
  A                                                    167               78.4
  B                                                    30                14.1
  C                                                    12                5.6
  TNM stage                                                              
  I                                                    137               64.3
  II                                                   42                19.7
  III                                                  34                16.0
  AST (μ/L)                      51.9 (12.3--182.6)                      
  ALT (μ/L)                      47.3 (5.6--168.4)                       
  Liver cirrhosis                                                        
  No                                                   98                46.0
  Yes                                                  115               54.0

AFP, alpha‐fetoprotein; BCLC, Barcelona Clinic Liver Cancer; AST, aspartate transaminase; ALT, alanine transaminase.
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A total of 66 pairs of resected HCC and adjacent nonneoplastic liver tissues were collected from patients who had undergone hepatectomies for the curative treatment of HCC at the Cancer Center of SYSU from 2012 to 2014. None of the patients received neoadjuvant therapies, such as radiotherapy or chemotherapy, before surgery. Informed consent was obtained from patients regarding the use of their liver specimens for research.

Follow‐up {#cam41521-sec-0004}
---------

The average postoperative follow‐up time in our study was 60.74 months. The longest postoperative follow‐up time was 126 months. Our primary study endpoint was the last follow‐up without recurrence or death. Overall survival (OS) was defined as the time until postoperative death or the last follow‐up. Time to recurrence (TTR) was defined as the interval between surgery and recurrence or between surgery and the last follow‐up for patients without recurrence. Postoperative follow‐up included abdominal ultrasound examinations or computed tomography studies every 3 months, serum alpha‐fetoprotein (AFP) measurements every 1--3 months, and hepatic artery angiography, bone imaging, or chest CT examination if necessary. If cancer recovery is to be achieved, it is considered necessary to use various treatments, including repeated hepatectomy, transcatheter arterial embolization, percutaneous ablation, and radiotherapy [19](#cam41521-bib-0019){ref-type="ref"}.

Immunohistochemistry {#cam41521-sec-0005}
--------------------

Resected surgical specimens were fixed in formalin and embedded in paraffin. Then, the specimens were cut into 4‐μm sections and placed onto glass slides. The sections were sequentially dehydrated with xylene, paraffin, and ethanol and then rehydrated with a graded series of alcohol. Next, the tissue slides were treated with fresh 0.3% hydrogen peroxide solution for 10 min to block the endogenous peroxidase and subjected to antigen repair in 0.01 mol/L sodium citrate buffer (pH 6.0) for 25 min using a microwave oven.

The sections were then incubated with anti‐MCT4 antibody (1:500 dilution; Santa Cruz, Cat. \# sc‐376101, Delaware Ave, CA, USA) or anti‐GLUT1 antibody (1:500 dilution; Abcam, Cat. \# ab652, Cambridge, U.K.) overnight at 4°C. Next, the tissue sections were incubated with HRP‐labeled anti‐mouse/rabbit secondary antibody (Dako, Cat. \# K5007, Glostrup, Denmark) for 1 h at room temperature. The reaction product was visualized using a nonbiotin horseradish peroxidase assay system according to the manufacturer\'s protocol, and the brown color indicates positive staining. All sections were counterstained with Mayer\'s hematoxylin and fixed in nonaqueous fixative.

H‐score [20](#cam41521-bib-0020){ref-type="ref"} was used for semiquantitative analysis of immunoreactivity of MCT4 and GLUT1. The score was obtained using the formula: 3 × percentage of strongly staining +2 × percentage of moderately staining +1 × percentage of weakly staining, giving a range of 0--300. Positive immunoreactivity was defined as H‐score\>0. Score was independently obtained by two of different professional pathologists who were blinded to the clinical data.

RNA isolation and quantitative real‐time PCR {#cam41521-sec-0006}
--------------------------------------------

Total RNA was isolated from tissues and cell lines using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). RNA (2 μg) was reverse‐transcribed using a SuperScript^®^ III First‐Strand Synthesis System (Invitrogen Life Technologies) according to the manufacturer\'s instructions. For real‐time PCR assays, cDNA was subjected to PCR amplification using SYBR Green (Toyobo, Kita‐Ku, Osaka, Japan) and a Roche LightCycler 480 System. GAPDH was used as an internal control. The primers were as follows:

MCT4 Forward: GTCATCTCTCTGCCCCACATReverse: AGCACGGTCAATGAGAACAA

GLUT1 Forward: TTATTGCCCAGGTGTTCGGCReverse: GTAGCAGGGCTGGGATGAAG

GAPDH Forward: GGTATGACAACGAATTTGGCReverse: GAGCACAGGGTACTTTATTG

Statistical analysis {#cam41521-sec-0007}
--------------------

IBM SPSS (version 22; IBM Corporation, Armonk, NY, USA) and GraphPad Prism (version 7; GraphPad Software, La Jolla, CA, USA) were used for statistical analyses. OS and TTR curves were generated according to the Kaplan--Meier method, and the differences between the curves were analyzed by log‐rank test. Using the Cox proportional hazards model, significant prognostic factors determined by univariate analysis were entered into the multivariate analysis. The relationship between MCT4/GLUT1 expression and various clinicopathological parameters was analyzed by chi‐square test or Fisher\'s exact test. Pearson correlation analysis was used to analyze the correlation between MCT4 and GLUT1 staining scores. The results were considered statistically significant at *P* \< 0.05.

Results {#cam41521-sec-0008}
=======

GLUT1 and MCT4 expression in HCC tumors and nontumor tissues {#cam41521-sec-0009}
------------------------------------------------------------

Immunohistochemical (IHC) staining was used to determine the expression of MCT4 and GLUT1 in 213 HCC samples (tumor and adjacent nontumor tissues). We found clear and distinguishable membrane staining for both MCT4 and GLUT1 in tumor tissue but weakened staining in the adjacent hepatocytes (Fig. [1](#cam41521-fig-0001){ref-type="fig"}A and B). MCT4 expression was significantly higher in tumor tissues (median score = 68.0) than in adjacent nontumor tissues (median score = 0.0; *P \< *0.001; Fig. [1](#cam41521-fig-0001){ref-type="fig"}C). Similar results were found for GLUT1 (median score: tumor tissues \[T\] = 43.0, nontumor tissues \[N\] = 9.0; *P* \< 0.001; Fig. [1](#cam41521-fig-0001){ref-type="fig"}D). These data indicate that GLUT1 expression and MCT4 expression are upregulated during tumorigenesis.

![IHC characteristics of MCT4 and GLUT1 in HCC specimens. (A, B) IHC assays of MCT4 (A) and GLUT1 (B) expression in tumor (T) and adjacent nontumor tissues (N). (A) MCT4 expression levels in the tumor (T) tissues are significantly higher than those in the adjacent nontumor tissues (N) (40×). The bottom panel shows an enlargement of the indicated area (200×). (B) GLUT1 expression levels in the tumor (T) tissues are significantly higher than those in the adjacent nontumor tissues (N) (40×). The bottom panel shows an enlargement of the indicated area (200×). (C, D) MCT4 (C) and GLUT1 (D) expression levels in tumor (T) tissue are significantly higher than those in adjacent nontumor tissue (N). The IHC H‐scores are shown as mean with range (bars); \*\*\* indicates *P* \< 0.01.](CAM4-7-5339-g001){#cam41521-fig-0001}

MCT4/GLUT1 expression and its correlation with clinicopathological features {#cam41521-sec-0010}
---------------------------------------------------------------------------

Table [1](#cam41521-tbl-0001){ref-type="table"} summarizes the clinicopathological features of 213 patients with HCC. The median follow‐up time was 60.74 months (range, 1.6--126 months). During follow‐up, 118 (55.4%) patients died, and 104 (48.8%) patients were diagnosed with tumor recurrence. The median OS and TTR for patients were 61.6 and 22.2 months, respectively. Patients were divided into two groups according to the level of MCT4 and GLUT1 expression. The cutoff value of MCT4 and GLUT1 expression was 87.25 and 57.75, respectively, as determined by the receiver operating characteristic (ROC) curve. High expression levels of MCT4 and GLUT1 were present in 47.4% (101/213) and 59.2% (126/213) of all cases. To further evaluate the GLUT1/MCT4 expression patterns in HCC tumor tissues and adjacent nonneoplastic tissues, we also examined their levels in 66 pairs of matched HCC tumor and nontumor specimens by quantitative real‐time PCR. We found that the expression levels of MCT4 were remarkably higher in the HCC tumor tissues than in the matched adjacent nonneoplastic tissues (Fig. [2](#cam41521-fig-0002){ref-type="fig"}B). Moreover, the MCT4 mRNA levels in tumor tissues were significantly higher in patients with a tumor diameter \>5 cm than in those with a tumor diameter ≤5 cm (*P* \< 0.01; Fig. [2](#cam41521-fig-0002){ref-type="fig"}B). GLUT1 mRNA levels were also significantly higher in patients with bigger tumors than in those with smaller tumors (*P* \< 0.05; Fig. [2](#cam41521-fig-0002){ref-type="fig"}C). Besides, the expression level of MCT4 mRNA was dissimilar in different Barcelona Clinic Liver Cancer (BCLC) stages of tumor tissue (*P* \< 0.05; Fig. [2](#cam41521-fig-0002){ref-type="fig"}B).

![Association between the expression levels of GLUT1 and MCT4 with clinicopathological features. (A) IHC staining for GLUT1 and MCT4 in patients with tumor diameters less than or greater than 5 cm. (B, C) Quantitative real‐time PCR was used to determine the relative MCT4 expression in 66 pairs of HCC tumors and matched nontumor tissues, the correlation between tumor size as well as BCLC stage and MCT4 expression levels, and the correlation between tumor size and GLUT1 expression. Each point represents a sample. (B) MCT4 levels in HCC tissues were significantly higher than those in nontumor tissues (left two columns), and MCT4 was more highly expressed (middle two columns) in tumor samples larger than 5 cm in diameter. (C) Similar results were observed for GLUT1 in the same samples. (D) The IHC H‐scores for GLUT1 (left two columns) and MCT4 (right two columns) in patients with tumor diameter less or more than 5 cm. (E) GLUT1 expression level is positively correlated with MCT4 expression (*n* = 213). The IHC H‐scores are expressed as mean ± standard error of mean (bars); \*\*\* indicates *P* \< 0.01, and \*\* indicates *P* \< 0.05.](CAM4-7-5339-g002){#cam41521-fig-0002}

We also analyzed the correlation between GLUT1/MCT4 expression status and clinicopathological features. MCT4 and GLUT1 expression levels correlated with tumor sizes (*P* \< 0.05; Table [2](#cam41521-tbl-0002){ref-type="table"}). Patients with larger tumors tended to have higher MCT4 or GLUT1 expression levels (*P* \< 0.01; Fig. [2](#cam41521-fig-0002){ref-type="fig"}A and D). In addition, MCT4 expression levels correlated with a poor BCLC stage (*P* = 0.002; Table [2](#cam41521-tbl-0002){ref-type="table"}). Furthermore, there was a positive correlation between MCT4 and GLUT1 expression (*r* = 0.562, *P* \< 0.001; Fig. [2](#cam41521-fig-0002){ref-type="fig"}E).

###### 

Correlation between MCT4/GLUT1 expression and clinicopathological parameters

  Clinicopathological variable   NO.   MCT4 expression levels   GLUT1 expression levels                          
  ------------------------------ ----- ------------------------ ------------------------- ----------- ----- ---- -----------
  Age (years)                                                                                                    
  ≤50                            103   57                       46                        0.435       42    61   0.984
  \>50                           110   55                       55                        45          65         
  Gender                                                                                                         
  Female                         31    16                       15                        0.907       13    18   0.894
  Male                           182   96                       86                        74          108        
  HBsAg                                                                                                          
  Negative                       31    15                       16                        0.613       11    20   0.511
  Positive                       182   97                       85                        76          106        
  Serum AFP (ng/mL)                                                                                              
  ≤400                           111   64                       47                        0.122       48    63   0.458
  \>400                          102   48                       54                        39          63         
  Tumor size (cm)                                                                                                
  ≤5                             90    38                       52                        **0.010**   30    60   **0.046**
  \>5                            123   74                       49                        57          66         
  Tumor number                                                                                                   
  Solitary                       148   77                       71                        0.807       60    88   0.891
  Multiple                       65    35                       30                        27          38         
  Microvascular invasion                                                                                         
  No                             172   93                       79                        0.257       74    98   0.185
  Yes                            41    18                       23                        13          28         
  Differentiation grade                                                                                          
  I+II                           119   62                       57                        0.874       49    70   0.912
  III+IV                         94    50                       44                        38          56         
  BCLC stage                                                                                                     
  0--A                           171   99                       72                        **0.002**   75    96   0.071
  B--C                           42    13                       29                        12          30         
  TNM stage                                                                                                      
  I                              137   68                       69                        0.247       55    82   0.780
  II--IV                         76    44                       32                        32          44         
  Recurrence                                                                                                     
  No                             109   48                       61                        **0.011**   37    72   **0.036**
  Yes                            104   64                       40                        50          54         
  AST (μ/L)                                                                                                      
  ≤40                            112   59                       53                        0.976       47    65   0.726
  \>40                           101   53                       48                        40          61         
  ALT (μ/L)                                                                                                      
  ≤40                            122   64                       58                        0.967       53    69   0.372
  \>40                           91    48                       43                        34          57         
  Liver cirrhosis                                                                                                
  No                             98    49                       49                        0.486       38    60   0.571
  Yes                            115   63                       115                       49          66         

AFP, alpha‐fetoprotein; BCLC, Barcelona Clinic Liver Cancer; AST, aspartate transaminase; ALT, alanine transaminase.

Bold values (*P* \< 0.05) are statistically significant.
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Prognostic value of MCT4 and GLUT1 expression in HCC {#cam41521-sec-0011}
----------------------------------------------------

Univariate analysis of MCT4/GLUT1 status and routine clinicopathological parameters showed that GLUT1 overexpression, MCT4 overexpression, high alpha‐fetoprotein levels, large tumor size, multiple tumors, poor BCLC stage, poor tumor--node--metastasis (TNM) stage, and microvascular invasion are unfavorable predictors of OS in patients with HCC (Table [3](#cam41521-tbl-0003){ref-type="table"}). In addition, high GLUT1 expression levels, high MCT4 expression levels, multiple tumors, and poor TNM stage were significantly associated with shorter TTR in patients with HCC (Table [3](#cam41521-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analyses of prognostic factors in HCC

  Variables                OS      TTR                                                               
  ------------------------ ------- ---------------------- ----------- ------- ---------------------- -----------
  Age (years)              0.795                                      0.301                          
  Gender                   0.866                                      0.660                          
  HBsAg                    0.277                                      0.934                          
  Serum AFP (ng/mL)        0.020                          N.A.        0.061                          
  Tumor size (cm)          0.001   1.900 (1.122--3.215)   **0.017**   0.097                          
  Tumor number             0.000   1.657 (1.061--2.587)   **0.026**   0.028                          N.A.
  Microvascular invasion   0.001   2.037 (1.267--3.272)   **0.003**   0.000   2.508 (1.457--4.316)   **0.001**
  Differentiation grade    0.569                                      0.406                          
  BCLC stage               0.007   1.547 (1.023--2.337)   **0.038**   0.892                          
  TNM stage                0.015                          N.A.        0.011                          N.A.
  AST (μ/L)                0.815                                      0.929                          
  ALT (μ/L)                0.348                                      0.991                          
  Liver cirrhosis          0.372                                      0.287                          
  MCT4 expression          0.001   1.617 (1.102--2.374)   **0.014**   0.004   1.930 (1.091--3.414)   **0.024**
  GLUT1 expression         0.020                          N.A.        0.044                          N.A.

OS, overall survival; TTR, the time to recurrence; HR, hazard ratio; CI, confidence interval; N.A., not applicable; MCT4, monocarboxylate transporter 4; GLUT1, glucose transporter 1.

Univariate analysis, Cox proportional hazards regression model. Multivariate analysis, Cox proportional hazards regression model. Variables were adopted by univariate analysis.

Bold values (*P* \< 0.05) are statistically significant.
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Kaplan--Meier survival curves showed that patients with high GLUT1 expression levels had lower OS (*P* = 0.02; Fig. [3](#cam41521-fig-0003){ref-type="fig"}A) and higher TTR rates (*P* = 0.044; Fig. [3](#cam41521-fig-0003){ref-type="fig"}B). The 5‐year OS and TTR rates in the high‐MCT4 expression group were 40.7% and 43.4%, respectively, which were significantly lower than those in the low‐MCT4 expression group (72.0% and 61.9%, respectively). We further explored the prognostic value of MCT4 with different BCLC stages of patients with HCC. Of the 171 patients at stages 0--A, 75 were identified as having positive MCT4 expression in tumor cells. Patients with positive MCT4 expression in tumor cells had a poorer surgical prognosis than those with negative MCT4 expression in tumor cells (*P* = 0.033; Fig. [3](#cam41521-fig-0003){ref-type="fig"}C); however, similar results could not be verified in the 42 patients at stages B--C (*P* = 0.455; Fig. [3](#cam41521-fig-0003){ref-type="fig"}D). Moreover, high GLUT1 expression levels indicated poorer OS (*P* \< 0.001; Fig. [3](#cam41521-fig-0003){ref-type="fig"}E) and higher TTR rates (*P* = 0.004; Fig. [3](#cam41521-fig-0003){ref-type="fig"}F). The 5‐year OS rates for the high‐ and low‐GLUT1 expression groups were 36.4% and 71.2%, respectively. These findings suggest that MCT4 and GLUT1 are important prognostic markers in patients with HCC. We evaluated whether MCT4 expression and GLUT1 expression were independently predictive of OS and TTR in patients with HCC using the multivariate Cox model. The results showed that MCT4 expression was an independent prognostic factor for OS in patients with HCC (hazard ratio \[HR\] = 1.617, 95% confidence interval \[CI\] = 1.102 ± 2.374, *P* = 0.014; Table [3](#cam41521-tbl-0003){ref-type="table"}).

![Prognostic significance of MCT4 expression and GLUT1 expression. (A, B) HCC patients with high MCT4 expression levels have a poor OS (A) and short TTR (B). (C, D) Kaplan--Meier analysis of the correlation between MCT4 expression in tumor cells and OS in BCLC stages 0--A (C) and stages B--C (D). (E, F) HCC patients with high GLUT1 expression levels have a poor OS (E) and short TTR (F).](CAM4-7-5339-g003){#cam41521-fig-0003}

Prognostic significance of the metabolic index {#cam41521-sec-0012}
----------------------------------------------

The metabolism of cancer cells is very different from that of normal cells [21](#cam41521-bib-0021){ref-type="ref"}. Cancer cell energy is mainly supplied by anaerobic glycolysis, and the synthesis of fatty acids and glutamine is also higher than that in normal cells [22](#cam41521-bib-0022){ref-type="ref"}; in this process, glucose and lactate metabolism play a leading role [23](#cam41521-bib-0023){ref-type="ref"}. It is believed that the transmembrane transport of MCT4 via proton‐linked lactate plays a key role in maintaining glycolysis metabolism [24](#cam41521-bib-0024){ref-type="ref"}, whereas GLUT1 is one of the most important glucose transporters in tumor cells [25](#cam41521-bib-0025){ref-type="ref"}. Therefore, we incorporated GLUT1 and MCT4 expression status into the metabolic indices to assess the combined effects of GLUT1 and MCT4 on HCC. Low and high expression levels of MCT4 and GLUT1 were designated as 0 and 1, respectively. Subsequently, MCT4 and GLUT1 indices were added to obtain metabolic indices of 0--2. Patients were thus divided into three groups: 0, low MCT4 and low GLUT1 expression (*n* = 50); 1, low MCT4 and high GLUT1 expression or high MCT4 and low GLUT1 expression (*n* = 99); and 2, high GLUT1 and high MCT4 expression (*n* = 55). Kaplan--Meier survival analysis showed that patients with high metabolic indices had poor OS (*P* = 0.001; Fig. [4](#cam41521-fig-0004){ref-type="fig"}A) and TTR rates (*P* = 0.007; Fig. [4](#cam41521-fig-0004){ref-type="fig"}B). In addition, multivariate analysis showed that the metabolic parameters were independent negative prognostic factors for both OS (HR = 1.617, 95% CI = 1.102--2.374, *P* = 0.006) and TTR (HR = 1.348, 95% CI = 1.079 ± 1.685, *P* = 0.009) (Table [4](#cam41521-tbl-0004){ref-type="table"}). We also divided the patients into two subgroups according to tumor sizes. Patients with a tumor diameter \>5 cm had a poorer prognosis than those with a tumor diameter ≤5 cm. Furthermore, the effect of the metabolic indices of the tumor cells on prognosis was examined in the two subgroups. The results showed that patients with positive metabolic index expression in tumor cells may have significantly shorter OS rates than those with negative metabolic index expression in tumor cells in the ≤5‐cm and \>5‐cm subgroups (Fig. [4](#cam41521-fig-0004){ref-type="fig"}C--F). In general, the metabolic index is a potent prognostic factor for OS and TTR in patients with HCC.

![Prognostic significance of the metabolic index. (A, B) HCC patients with a high metabolic index have a poor OS (A) and short TTR (B) (*n* = 213). (C, D) Kaplan--Meier analysis of OS and TTR in patients according to tumor size, with 5 cm as the cutoff value. The OS ratio represents the prognostic significance of the metabolic index in the group with tumor size ≤5 cm (C) and the group with tumor size \>5 cm (D). (E, F) The TTR ratio represents the prognostic significance of the metabolic index in the group with tumor size ≤5 cm (E) and the group with tumor size \>5 cm (F).](CAM4-7-5339-g004){#cam41521-fig-0004}

###### 

Univariate and multivariate analyses of prognostic factors in HCC

  Variables                OS      TTR                                                               
  ------------------------ ------- ---------------------- ----------- ------- ---------------------- -----------
  Age (years)              0.795                                      0.301                          
  Gender                   0.866                                      0.660                          
  HBsAg                    0.277                                      0.934                          
  Serum AFP (ng/mL)        0.020                          N.A.        0.061                          
  Tumor size (cm)          0.001   1.889 (1.120--3.186)   **0.017**   0.097                          
  Tumor number             0.000   1.691 (1.081--2.645)   **0.021**   0.028                          N.A.
  Microvascular invasion   0.001   2.021 (1.260--3.244)   **0.003**   0.000   2.410 (1.405--4.134)   **0.001**
  Differentiation grade    0.569                                      0.406                          
  BCLC stage               0.007   1.542 (1.021--2.330)   **0.040**   0.892                          
  TNM stage                0.015                          N.A.        0.011                          N.A.
  AST (μ/L)                0.815                                      0.929                          
  ALT (μ/L)                0.348                                      0.991                          
  Liver cirrhosis          0.372                                      0.287                          
  Metabolic index          0.001   1.617 (1.102--2.374)   **0.006**   0.007   1.348 (1.079--1.685)   **0.009**

OS, overall survival; TTR, the time to recurrence; HR, hazard ratio; CI, confidence interval; N.A., not applicable; MCT4, monocarboxylate transporter 4; GLUT1, glucose transporter 1.

Univariate analysis, Cox proportional hazards regression model. Multivariate analysis, Cox proportional hazards regression model. Variables were adopted by univariate analysis.

Bold values (*P* \< 0.05) are statistically significant.
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Discussion {#cam41521-sec-0013}
==========

Abnormal glucose metabolism (glucose metabolism reprogramming) plays a key role in tumorigenesis and progression [26](#cam41521-bib-0026){ref-type="ref"}, and its regulatory mechanism has been a hot topic in the field of oncology. Cancer cell production of lactate, the primary end product of glycolysis, creates an acidic environment that favors tumor invasion and inhibits anticancer immune effects, thus supporting the growth and metastasis of cancer cells [10](#cam41521-bib-0010){ref-type="ref"}, [27](#cam41521-bib-0027){ref-type="ref"}. Previous studies report that MCT4, an efficient lactate exporter, promotes the hostile acidic microenvironment for glycolysis and tumor growth [28](#cam41521-bib-0028){ref-type="ref"}. In addition, a functional study showed that GLUT1, a key transporter in glucose metabolism, is crucial for HCC cell proliferation and migration [29](#cam41521-bib-0029){ref-type="ref"}. Recent studies have shown that MCT4 is highly expressed in patients with liver cancer and that high expression levels of MCT4 are a negative prognostic marker for OS and DFS [30](#cam41521-bib-0030){ref-type="ref"}. Therefore, whether MCT4 plays an important role in glycometabolism in hepatocellular carcinoma and its close relationship with GLUT1 is worth exploring. According to the BCLC staging system, patients in stages 0 and A are considered to be in the early stages of HCC and have a better outcome after radical resection. However, some of these early patients have poor prognosis in clinical practice. Our results suggest that the expression of MCT4 in tumor cells predicts worse survival in early patients (Fig [3](#cam41521-fig-0003){ref-type="fig"}C and D). Therefore, the findings of this study suggest that measuring the expression of MCT4 in tumor cells can discriminate poor prognosis in patients with early‐stage HCC. In the present study, we examined the expression of two important transporters, MCT4 and GLUT1, to determine their metabolic status in HCC and assess their prognostic value. Our data show that MCT4 and GLUT1 expression levels are significantly higher in HCC cells than in adjacent nontumorous hepatocytes. Due to the important functions of GLUT1 and MCT4, we found that patients with high MCT4/GLUT1 expression levels had shorter OS and TTR. In addition, the metabolic index that correlated with MCT4 and GLUT1 expression is an independent prognostic factor for OS and TTR in HCC.

Regarding the routine clinical and pathological features of HCC, the expression levels of MCT4 and GLUT1 are closely related to tumor size. MCT4 and GLUT1 are required for cell proliferation and tumor growth, and due to the high concentration of nutrients in cancer cells, GLUT1 and MCT4 may promote tumor microenvironment formation by regulating the concentration of nutrients [27](#cam41521-bib-0027){ref-type="ref"}. Furthermore, large tumors may promote the expression of MCT4 and GLUT1 [29](#cam41521-bib-0029){ref-type="ref"}. Large tumors are usually associated with hypoxia and are known to induce HIF1α expression, which is associated with tumor size, and to promote GLUT1 and MCT4 expression in HCC [12](#cam41521-bib-0012){ref-type="ref"}. In addition, in chronically infected HBV and HCV livers, cirrhosis accompanies significantly reduced oxygen supply [31](#cam41521-bib-0031){ref-type="ref"}. Subsequent microenvironment‐induced HIF1α activates vascular endothelial growth factor and cyclooxygenase transcription to promote angiogenesis stabilization and activate matrix metalloproteinases [32](#cam41521-bib-0032){ref-type="ref"}. Consistent with these studies, we found that GLUT1 and MCT4 are highly expressed in tumors larger than 5 cm in diameter. In addition, hypoxia is associated with the upregulation of glycolysis [33](#cam41521-bib-0033){ref-type="ref"}. Lactate, a glycolysis product, triggers MCT4 expression through the activation of c‐Myc; this finding indicates that MCT4 is closely linked to glucose metabolism [34](#cam41521-bib-0034){ref-type="ref"}. In this study, we found a positive correlation between MCT4 expression and GLUT1 expression. These data suggest that there is a positive feedback loop between tumor growth and the upregulation of MCT4/GLUT1. This positive feedback loop may be important for HCC progression.

In conclusion, GLUT1 and MCT4 expression levels are significantly higher in tumors than in adjacent nontumorous hepatocytes, particularly in hepatoma tumors with diameters greater than 5 cm. Patients with high GLUT1 or MCT4 expression levels had a poor OS and short TTR, and the expression of MCT4 in tumor cells might discriminate poor prognosis in patients with early‐stage HCC. In addition, metabolic indices were independent prognostic factors for OS and TTR. Our study shows that the expression of GLUT1 and MCT4 determines the metabolic status of the tumor, and the combined expression of these two proteins may be a good prognostic biomarker and therapeutic target for patients with HCC.
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